Scientific intelligence record
Experience 2.0
GLP-1/glucagon receptor agonist
Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic dysfunction-associated steatohepatitis and related metabolic outcomes. Liver histology, noninvasive markers, weight, and cardiovascular risk factors are distinct endpoints.
Record status
Traceability partial
Last meaningful update: 9/23/2026
Ranked research corpus
32
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
32 matching records · ranked 2026-09-18
Page 1 of 2
Europe PMC · 2026 · PMID 42529769 · DOI 10.7759/cureus.111728
synthesis
WPF seed · 2026 · PMID 41879841 · DOI 10.1007/s00210-026-05257-1
synthesis
OpenAlex · 2026 · Source ID doi:10.1016/s0168-8278(26)01936-7 · DOI 10.1016/s0168-8278(26)01936-7
human-interventional
Europe PMC · 2026 · PMID 41696398 · DOI 10.1016/j.abrep.2026.100671
synthesis
OpenAlex · 2026 · Source ID doi:10.1016/s0168-8278(26)00451-4 · DOI 10.1016/s0168-8278(26)00451-4
human-interventional
OpenAlex · 2026 · Source ID doi:10.1016/s0168-8278(26)00326-0 · DOI 10.1016/s0168-8278(26)00326-0
human-interventional
WPF seed · 2026 · PMID 41661442 · DOI 10.1007/s40262-025-01615-z
preclinical-animal
OpenAlex · 2026 · Source ID doi:10.1016/s0168-8278(26)01885-4 · DOI 10.1016/s0168-8278(26)01885-4
human-interventional
OpenAlex · 2025 · Source ID doi:10.2337/db25-228-or · DOI 10.2337/db25-228-or
laboratory-mechanistic
OpenAlex · 2025 · Source ID doi:10.2337/db25-748-p · DOI 10.2337/db25-748-p
contextual-unclassified
OpenAlex · 2025 · Source ID doi:10.2337/db25-749-p · DOI 10.2337/db25-749-p
preclinical-animal
OpenAlex · 2025 · Source ID doi:10.2337/db25-778-p · DOI 10.2337/db25-778-p
laboratory-mechanistic
Europe PMC · 2025 · PMID 40063921 · DOI 10.36740/merkur202501117
preclinical-animal
WPF seed · 2025 · PMID 39002641 · DOI 10.1016/j.jhep.2024.07.006
preclinical-animal
Europe PMC · 2025 · Source ID doi:10.64898/2025.12.22.25342824 · DOI 10.64898/2025.12.22.25342824
synthesis
WPF seed · 2025 · PMID 40081498 · DOI 10.1016/j.peptides.2025.171380
preclinical-animal
Europe PMC · 2025 · PMID 41362110 · DOI 10.1002/jcsm.70147
human-interventional
Europe PMC · 2025 · PMID 40734920 · DOI 10.7573/dic.2025-4-8
human-interventional
OpenAlex · 2025 · Source ID doi:10.1016/s0168-8278(25)01709-x · DOI 10.1016/s0168-8278(25)01709-x
preclinical-animal
Europe PMC · 2025 · PMID 41113119 · DOI 10.1016/j.jhepr.2025.101483
human-interventional
WPF seed · 2025 · PMID 41237796 · DOI 10.1016/S0140-6736(25)02114-2
preclinical-animal
Europe PMC · 2025 · PMID 41352959 · DOI 10.1016/s0140-6736(25)02304-9
human-interventional
OpenAlex · 2024 · Source ID doi:10.2337/db24-228-or · DOI 10.2337/db24-228-or
laboratory-mechanistic
OpenAlex · 2024 · Source ID doi:10.2337/db24-262-or · DOI 10.2337/db24-262-or
human-interventional
WPF seed · 2024 · PMID 39676791 · DOI 10.4103/ijem.ijem_442_23
laboratory-mechanistic
governance and regulatory context
No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.
No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review.
Pemvidutide evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
APA
World Peptide Foundation. (n.d.). Pemvidutide — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 23, 2026.) https://www.worldpeptidefoundation.org/directory/pemvidutide
AMA / Vancouver
World Peptide Foundation. Pemvidutide — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 23, 2026. https://www.worldpeptidefoundation.org/directory/pemvidutide
Featured tiered studies
0
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
5
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
5
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
32
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
0
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
5
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
5
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
Pemvidutide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasContent-verified record concerning Pemvidutide: "Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial." Abstract excerpt: This was a double-blind 12-week extension of a randomized, placebo-controlled, 12-week trial of pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). Completers of a double-blind trial of pemvidutide in MASLD, who were previously randomized 1:1:1:1 to pemvidutide at 1.2 mg, 1.8 mg, or 2.4 mg, or
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
systematic_review_or_meta_analysis
2026 · regulatory · Temporal status not established
European Union — EMA
2026 · regulatory · Temporal status not established
United States — FDA
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 5 domain conclusions and 0 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the Pemvidutide evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
European Union — EMA
Regulator: EMA
As of: 9/23/2026 · Temporal status not established
United States — FDA
Regulator: FDA
As of: 9/23/2026 · Temporal status not established
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 4:00:27 AM
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
Randomized study in MASLD; endpoint and follow-up require full-text appraisal.
Content-verified record concerning Pemvidutide: "Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study." Abstract excerpt: GLP-1-glucagon dual receptor agonists such as pemvidutide have shown promise in treating metabolic dysfunction-associated steatohepatitis (MASH). The aim of this trial was to assess the effects of pemvidutide on MASH resolution and fibrosis improvement in patients with liver fibrosis stage F2 or F3 MASH at 24 weeks of treatment. IMPACT is an ongoing 48-week international, randomised, double-blind,
Content-verified record concerning Pemvidutide: "The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial." (identity confirmed; no abstract text available to excerpt.)
Content-verified record concerning Pemvidutide: "Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials." Abstract excerpt: Metabolic dysfunction-associated steatohepatitis (MASH) contributes substantially to liver and cardiometabolic disease. Pemvidutide, a dual GLP-1/glucagon receptor agonist, may provide combined hepatic and systemic benefits. We conducted a meta-analysis of randomized controlled trials comparing pemvidutide versus placebo in adults with MASLD/MASH. Data were pooled using random-effects models to es